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ABSTRACT 
Background: Oral anticoagulation is the mainstay of stroke prevention in atrial fibrillation 
(AF), but must be balanced against the associated bleeding risk. Several risk scores have been 
proposed for prediction of bleeding events in patients with AF. 
Objectives: To compare the performance of contemporary clinical bleeding risk scores in 
18,113 patients with AF randomized to dabigatran 110 mg, 150 mg or warfarin in the RE-LY 
trial. 
Methods: HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES bleeding risk scores were 
calculated based on clinical information at baseline. All major bleeding events were centrally 
adjudicated. 
Results: There were 1,182 (6.5%) major bleeding events during a median follow-up of 2.0 
years. For all the four schemes, high-risk subgroups had higher risk of major bleeding (all 
p<0.001). The ORBIT score showed the best discrimination with c-indices of 0.66, 0.66 and 
0.62, respectively, for major, life-threatening and intracranial bleeding, which were 
significantly better than for the HAS-BLED score (difference in c-indices: 0.050, 0.053 and 
0.048, respectively, all p<0.05). The ORBIT score also showed the best calibration compared 
with previous data. Significant treatment interactions between the bleeding scores and the 
risk of major bleeding with dabigatran 150 mg BD versus warfarin were found for the 
ORBIT (p=0.0019), ATRIA (p<0.001), and HEMORR2HAGES (p<0.001) scores. HAS-
BLED score showed a non-significant trend for interaction (p=0.0607). 
Conclusions: Among the current clinical bleeding risk scores, the ORBIT score 
demonstrated the best discrimination and calibration. All the scores demonstrated, to a 
variable extent, an interaction with bleeding risk associated with dabigatran or warfarin. 
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INTRODUCTION 
 
Atrial fibrillation (AF) is associated with a significant increase in risk for stroke and 
thromboembolic events which is variable between different patients [1–3]. Treatment with 
oral anticoagulant (OAC) is the cornerstone in prevention of thromboembolic events in AF 
patients at an increased risk of stroke [1]. However, OAC treatment is unavoidably associated 
with an increased risk of bleeding, regardless of OAC type used[4,5]. 
 
Non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be safer than 
warfarin in relation to major bleeding events, particularly intracranial hemorrhage[6]. All of 
the NOACs are now recommended in all guidelines[1–3,7,8] for stroke prevention in AF and 
in some guidelines in preference to vitamin K antagonist for the majority of AF 
patients[1,3,8]. 
 
Baseline evaluation of bleeding risk is mandatory [1–3,7,8] during the decision-making 
process of prescribing OAC therapy, as well as throughout follow-up, as bleeding risk may 
change over time. In recent years several clinical prediction scores have been developed and 
validated in large cohorts, and can be used as tools for bleeding risk evaluation in AF 
patients, namely, “Hypertension, Abnormal liver/renal function, Stroke, Bleeding, Labile 
International Normalized Ratio, Elderly, Drugs or alcohol” (HAS-BLED) [9], “Older age, 
Reduced haemoglobin/haematocrit/anaemia, Bleeding history, Insufficient kidney function, 
Treatment with platelets” (ORBIT) [10], “Anticoagulation and Risk Factors in Atrial 
Fibrillation” (ATRIA) Bleeding [11], “Hepatic or renal disease, Ethanol abuse, Malignancy 
history, Older (age >75), Reduced platelet count or function, Rebleeding risk, Hypertension, 
Anaemia, Genetic factors, Excessive fall risk, Stroke history” (HEMORR2HAGES) [12] and 
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“Age, Biomarkers, Clinical history” (ABC)-bleeding[13] scores. Currently, most of the 
international guidelines propose the use of clinical tools to assess bleeding risk [1,3,7]. So far 
there are few studies which have focused on comparisons and validation of the different 
bleeding scores in patients treated with NOACs [10,14,15]. 
 
The aims of the current analyses are two-fold: (1) to compare the predictive performance of 
HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES bleeding scores in patients with AF 
enrolled in the “Randomized Evaluation of Long-term anticoagulant therapY” (RE-LY) 
Trial; and (2) to evaluate the interaction between predicted high risk of bleeding, according to 
the bleeding risk scores, and the effects on major bleeding by treatment with dabigatran 
(either 110 mg and 150 mg BID) or warfarin. 
 
METHODS 
 
Details about the study design and main results have been reported elsewhere[16,17]. Briefly, 
the RE-LY trial enrolled 18,113 patients with non-valvular AF who were randomized to 
receive OAC therapy with dabigatran 110 mg BID, dabigatran 150 mg BID or dose-adjusted 
warfarin (international normalized ratio (INR) target 2.0 to 3.0). The median duration of 
follow-up was 2.0 years. The study was conducted according to Good Clinical Practice 
recommendations and the Declaration of Helsinki. All enrolled patients were considered for 
this post-hoc analysis of the RE-LY trial.  
 
The HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES scores were computed according 
to original definitions[9–12]. Details about the components, definitions, and risk categories 
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for the evaluated bleeding risk prediction scores are available in the web-only Supplementary 
Material. 
 
The primary outcome for this analysis was the occurrence of major bleeding, the primary 
safety endpoint in the RE-LY trial, defined according to the original study protocol as a 
reduction in the hemoglobin level of at least 20 g per liter, transfusion of at least 2 units of 
blood or symptomatic bleeding in a critical area or organ[17]. Life-threatening bleeding and 
intracranial bleeding were considered as secondary outcomes. Life-threatening bleeding was 
a subcategory of major bleeding that consisted of fatal bleeding, symptomatic intracranial 
bleeding, bleeding with a decrease in the hemoglobin level of at least 50 g per liter, or 
bleeding requiring transfusion of at least 4 units of blood or inotropic agents or necessitating 
surgery[17]. All bleeding events were centrally adjudicated by an independent clinical events 
committee blinded to treatment assignment. The current analyses have been performed 
incorporating the additional events reported and adjudicated after the release of the study 
main results[18]. 
 
Statistical Analysis 
Categorical variables have been reported as counts and percentages, while continuous 
variables have been reported as median and interquartile range. Comparisons between 
categorical variables have been performed with chi-squared test, whilst comparisons between 
continuous variables were performed according to the Wilcoxon rank sum test. Outcomes are 
expressed as annualized incidence rates.  
 
The discriminative ability of the scores was assessed and compared using Harrell’s C-index. 
Confidence interval for differences between C-indexes was obtained using 1000 bootstrap 
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samples. Calibration was evaluated by plots of major bleeding events rates per 100 patient-
years (95% confidence interval) observed in the RE-LY trial vs. the previously published 
event rates from the original derivation cohorts. Interactions between study treatments and 
risk scores (in clinically meaningful risk categories as well as in continuous form) regarding 
study outcomes were evaluated by Cox proportional hazards models. As reported in the 
Supplementary Materials, a sensitivity analysis for HAS-BLED with alternative definition of 
“Labile INR” criterion was performed. A 2-sided p<0.05 was considered statistically 
significant and since all analyses were exploratory, there were no adjustments for multiple 
comparisons. All analyses were performed with SAS software, version 9.4 (SAS Institute 
Inc., Cary, NC).   
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RESULTS 
 
A total of 1182 (6.5%) major bleeding events occurred and were adjudicated, with an overall 
annual rate of 3.31%/year. Among these events, 47.0% (n= 555) were life-threatening 
bleeding events with an overall annual rate of 1.55%/year. Intracranial bleeds occurred in 157 
(13.3% of major bleeding events), with an overall annual rate of 0.44%/year events. Clinical 
characteristics of patients according to major bleeding occurrence are summarized in Table 1. 
 
As previously reported elsewhere, patients reporting a major bleeding occurrence were more 
likely to be older, hypertensive and with a previous history of stroke/transient ischemic 
attack/systemic embolic event[17,19]. Patients who experienced major bleeding had a higher 
thromboembolic risk (p<0.0001) (Table 1). Results were similar when separately analyzed by 
randomized treatment (Table S1). 
 
Risk Score Distribution and Bleeding Outcomes 
HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES median scores were higher (all 
p<0.0001) in patients that experienced major bleeding compared to those patients who did 
not (Table 2). Accordingly, the proportion of patients assigned to the high-risk category was 
consistently higher for those that reported major bleeding during follow-up for all four 
bleeding risk scores (all p<0.0001). 
 
Analysing the bleeding risk scores distribution in relation to the randomized treatment 
yielded similar results with higher values for the bleeding risk scores in patients that 
experienced major bleeding (Table S2). Similarly, the proportion allotted to high risk 
 9 
categories within each score was higher among the patients that reported a major bleeding 
occurrence for all the randomized treatments (Table S2). 
 
Discriminative Performance 
Predictive performances of the bleeding risk scores are reported in Table 3. All bleeding risk 
scores showed a significant, albeit, modest predictive capacity. Among the overall cohort, the 
best discrimination in predicting major bleeding occurrence was shown using the ORBIT 
score (c-index: 0.66). Stratifying the results according to the randomized treatment, all the 
bleeding risk scores demonstrated significant predictive ability for all randomized treatment 
groups (Table 3). The ORBIT score also demonstrated the best discriminative ability across 
randomized OAC treatment groups (c-indexes: 0.68, 0.70 and 0.62, for dabigatran 110 mg, 
dabigatran 150 mg and warfarin, respectively). Similar results were obtained for life-
threatening bleeding occurrence. For the intracranial bleeding outcome, all the scores had 
lower predictive ability, both in the overall population and in the randomized treatments 
subgroups (Table 3). The ORBIT score was consistently the best predictor for intracranial 
bleeding among the three treatment subgroups, while the predictive ability of the HAS-
BLED, ATRIA and HEMORR2HAGES was found to be broadly non-significant among 
patients randomized to both dabigatran 110 mg and dabigatran 150 mg. 
 
When comparing the discriminative abilities of the four bleeding scores (Table 4), the 
ORBIT score was consistently found to be significantly better than HAS-BLED, across the 
three bleeding outcomes (differences in c-indices: 0.050, 0.053 and 0.048, for major 
bleeding, life-threatening bleeding and intracranial bleeding, respectively). The ATRIA score 
performed better than HAS-BLED only for prediction of major bleeding, while differences in 
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the c-indexes for the other outcomes were non-significant. HEMORR2HAGES performed 
similarly to HAS-BLED for all the outcomes considered (Table 4). 
 
Calibration Analysis 
Evaluation of calibration, the comparison between estimated and actually observed event 
rates, for the four bleeding scores demonstrated that the ORBIT score had the best agreement 
over the range of bleeding risk when compared to the original derivation cohort [Figure 1]. 
Conversely, the ATRIA score showed the largest mismatch in calibration. The ATRIA and 
HAS-BLED scores, to different degrees, tended to overestimate the risk of bleeding. The 
HEMORR2HAGES score underestimated the risk of bleeding events, in particularly for those 
patients with a higher predicted risk [Figure 1]. 
 
Treatment Effect Interactions with Bleeding Risk Scores 
Major bleeding incidence rates progressively increased according to increasing scores for all 
the four bleeding risk score schemes [Figure 2, Panel A]. Compared to warfarin, incidence 
rates were found to be higher for patients assigned to dabigatran 150 mg BID according to 
the increasing score for all the schemes (p for interaction =0.0122, p<0.0001, p<0.0001 and 
p<0.0001 respectively for HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES). Similar 
results were reported for life-threatening bleeding [Figure 2, Panel B]. 
 
In patients assigned to dabigatran 110 mg BID, higher incidence rates were evident compared 
to warfarin based on increasing ORBIT and ATRIA scores (p for interaction=0.0051 and 
p=0.0047, respectively) [Figure 2, Panel A]. No significant interactions were found for life-
threatening bleeding for dabigatran 110 mg compared to warfarin [Figure 2, Panel B] or 
intracranial bleeding for both dabigatran 110 mg and 150 mg [Figure 2, Panel C]. 
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The interaction analyses demonstrated that the ORBIT, ATRIA and HEMORR2HAGES 
scores had a significant interaction with treatment on major bleeding when comparing 
patients assigned to dabigatran 150 mg with those randomized to receive warfarin (p=0.0019, 
p<0.0001 and p<0.0001, respectively) [Figure 3, Upper Panel]. Conversely, the HAS-BLED 
score showed a non-significant trend for interaction (p=0.0607) [Figure 3, Upper Panel]. 
Only the ATRIA score showed a significant treatment interaction in patients randomized to 
dabigatran 110 mg compared to those assigned to warfarin (p=0.0097) [Figure 3, Lower 
Panel].  
 
Similarly, ORBIT, ATRIA and HEMORR2HAGES high risk categories were found to be 
associated with life-threatening bleeding occurrence in patients assigned to dabigatran 150 
mg (p=0.0266, p=0.0021 and p=0.0073). HAS-BLED showed a trend in association, despite 
not reaching statistical significance (p=0.0574) (Table S3). No significant treatment 
interaction for life-threatening bleeding was found when comparing dabigatran 110 mg and 
warfarin according the four bleeding scores. No significant interaction was detected for the 
three randomized treatments groups across the four scores for the intracranial bleeding 
occurrence (Table S3). 
 
Sensitivity Analysis 
A sensitivity analysis was conducted for HAS-BLED using an alternative definition for labile 
INR (Tables S4-S5), according the INR value at randomization (see Supplementary Methods 
in Supplementary Materials). In this sensitivity analysis, a significant treatment interaction 
for the HAS-BLED score and major bleeding occurrence was found, with HAS-BLED high-
risk category patients assigned to receive dabigatran 150 mg, with a significant higher risk of 
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major bleeding occurrence compared to warfarin patients (p=0.0050) (Table S4, Right 
Column). 
 
DISCUSSION 
 
In this post-hoc analysis of the RE-LY cohort, we found that the HAS-BLED, ORBIT, 
ATRIA and HEMORR2HAGES bleeding scores had a significant, albeit modest, 
discriminative capacity in predicting major and life-threatening bleeding occurrences. All the 
bleeding risk scores identified groups with different risks of major and life-threatening 
bleeding outcomes, independently of treatment with dabigatran or warfarin. Among them, the 
ORBIT score demonstrated the best discriminative ability and the best calibration. The 
ORBIT, ATRIA and HEMORR2HAGES scores showed significant treatment interactions, 
comparing dabigatran 150 mg BID and warfarin according to the predicted bleeding risk at 
baseline, for the occurrence of major and life-threatening bleeding events. The HAS-BLED 
score showed a significant treatment interaction only when computed using the alternative 
“Labile INR” criterion, related to the current INR at randomization. 
 
Occurrence of major bleeding events is the most feared complication for physicians 
prescribing OAC[20] and physicians may often overestimate patients’ bleeding risk, leading 
to OAC under-prescription[21] and under-dosing [22]. Data from a large observational trial 
in USA, the “Outcomes Registry for Better Informed Treatment of Atrial Fibrillation” study, 
showed that the high risk of bleeding, as well as the previous history of bleeding, were 
amongst the most prevalent reasons for not prescribing OAC[23]. Similarly, data from the 
same cohort showed that the high risk of bleeding was one of the main reasons leading to 
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OAC discontinuation[24]. Indeed, the concern about major bleeding seems  to 
disproportionally outweigh the risk of stroke among some prescribing physicians[25].  
Nonetheless, high risk of bleeding alone should not be a sufficient reason to withhold OAC 
treatment. All major current guidelines strongly emphasize that all patients should be 
evaluated for bleeding risk at baseline[1–3,7,8], and recommend that modifiable and 
potentially modifiable bleeding risk factors are addressed in order to minimize the risk of 
bleeding[1]. It is proposed that patients identified as at high bleeding risk are monitored more 
closely. Bleeding risk should therefore not be considered as definite, but rather as a 
continuum, and bleeding risk assessment should routinely be repeated at follow-up visits and 
managed appropriately. In this setting, it is therefore fundamental to use well-calibrated and 
validated bleeding risk scores. Another important issue concerning clinical risk scores is the 
ease of use which may influence the uptake and generalizability of a score. However, the 
growing use of digital calculators and electronic medical charts in current practice will likely 
increase and facilitate the implementation of more precise risk models and integrated 
decision support tools. 
 
Bleeding risk prediction scores are considered by international guidelines as useful tools to 
identify those patients with a prevalent bleeding risk[1,3,7]. The performance of HAS-BLED, 
ATRIA and HEMORR2HAGES scores have been evaluated and validated in several previous 
studies [10,26–30]. Several comparisons have been performed between the bleeding risk 
scores among AF patients treated with vitamin K antagonist, in several different scenarios, 
both from real-life cohorts [31,32] and post-hoc or prospective analyses of randomized 
controlled trials[14,33–35] and have demonstrated overall modest predictive capacity for all 
the scores [31–35], with several of the previous analyses indicating that the HAS-BLED 
score performs better in those patients treated with vitamin K antagonist [31,33–35]. 
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To date there is limited data on the use of bleeding risk scores in patients treated with 
NOACs. The present analyses demonstrate that all the bleeding risk scores can separate 
groups with different risks of major bleeding and life-threatening bleeding in a large cohort 
of patients treated with either warfarin or a NOAC, namely dabigatran in the present study. 
The ORBIT score was validated in the “Rivaroxaban Once Daily Oral Direct Factor Xa 
Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism 
Trial in Atrial Fibrillation” study and demonstrated slightly better discriminative capacity 
than the HAS-BLED and ATRIA bleeding scores (c-indices: 0.67, 0.64, 0.66, 
respectively)[10]. Furthermore, the ORBIT score was also shown to outperform the HAS-
BLED score in another large cohort of patients treated with apixaban, in a subgroup analysis 
derived from the “Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation” study[13]. In the current RE-LY cohort, the ORBIT score showed the best 
predictive ability and calibration. Together with the previous evidence[10,13], our data seem 
to suggest that the ORBIT score has superior discrimination and calibration properties than 
HAS-BLED when applied to mixed cohorts of patients, treated with both warfarin and 
NOACs. 
 
The ORBIT, ATRIA, HEMORR2HAGES scores and to some extent the HAS-BLED score, 
managed to identify a group of high-risk patients that, when treated with dabigatran 150 mg 
were more likely to experience a major bleed. Conversely, the same high-risk patients had a 
lower bleeding risk when treated with dabigatran 110 mg. This clearly illustrates how 
dabigatran can be a safe alternative for AF patients even at a high risk of bleeding by using a 
more “personalized treatment” based on one of these bleeding scores when considering the 
most suitable dose. 
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Limitations 
The main limitation of the current analysis is its retrospective nature and therefore the 
original study design was not specifically powered to detect differences in the subgroups 
under consideration. In addition, this analysis was performed on a cohort of AF patients from 
a randomized controlled trial, thus our results may not be completely generalizable to the 
overall AF population. Also, additional cardiovascular biomarkers were not available in all 
patients and therefore the recently developed ABC-bleeding risk score[13] was not included 
in the present analyses. Finally, despite reporting overall significant predictive properties, all 
the scores demonstrated a rather modest prediction ability. 
 
CONCLUSIONS 
 
All the bleeding risk scores identified patient groups with different risks of major bleeding 
and life-threatening bleeding with modest and variable discriminative ability. The ORBIT 
score demonstrated superior discrimination and calibration in this large randomized clinical 
trial of AF patients. All the bleeding risk scores demonstrated, to a variable extent, a 
significant interaction with the bleeding risk associated with dabigatran or warfarin.  
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FIGURE LEGENDS 
 
Figure 1: Bleeding Risk Scores Calibration Between Derivation Cohorts and RE-LY 
Cohort Event Rates 
 
Figure 2: Major Bleeding Incidence Rates According Bleeding Risk Scores and 
Randomized Treatment 
Legend: Panel A) Major Bleeding; Panel B) Life-Threatening Bleeding; Panel C) Intracranial 
Bleeding; DE110= dabigatran etexilate 110 mg; DE150= dabigatran etexilate 150 mg; W= 
warfarin. 
 
Figure 3: Forest Plots for Treatment Interactions in Major Bleeding Occurrence 
According Bleeding Risk Scores Categories 
Legend: DE110= dabigatran etexilate 110 mg; DE150= dabigatran etexilate 150 mg.  
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Table 1: Baseline Characteristics According Major Bleeding Occurrence 
 Major Bleeding p-value 
 Yes 
N=1182 
No 
N=16931 
 
Age, (years) median [IQR] 76 [71-80] 72.0 [66-77] <0.0001 
Age ≥75 years, n (%) 670 (56.7) 6568 (38.8) <0.0001 
Female, n (%) 413 (34.9) 6185 (36.5) 0.27 
SBP, (mmHg) median [IQR] (18086)* 130 [118-140] 130 [120-140] 0.0046 
CrCL, (mL/min), median [IQR] (17375)* 59.9 [46.9-75.7] 69.1 [53.9-87.4] <0.0001 
Hypertension, n (%) 970 (82.1) 13313 (78.6) 0.0053 
Diabetes Mellitus, n (%) 354 (29.9) 3867 (22.8) <0.0001 
CAD, n (%) 449 (38.0) 4585 (27.1) <0.0001 
Previous Stroke/SEE/TIA, n (%) 289 (24.5) 3664 (21.6) 0.0238 
Symptomatic HF (NYHA≥2), n (%) 325 (27.5) 4579 (27.1) 0.73 
CrCL Category, n (%) (17375)* 
<50 mL/min 
50-79 mL/min 
≥80 mL/min 
 
360 (31.4) 
554 (48.3) 
234 (20.4) 
 
3060 (18.9) 
7743 (47.7) 
5424 (33.4) 
<0.0001 
History of Fall, n (%) 205 (17.4) 1842 (10.9) <0.0001 
Anemia, n (%) 327 (27.7) 2146 (12.7) <0.0001 
Malignancy, n (%) 171 (14.5) 1714 (10.1) <0.0001 
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Previous VKA Use, n (%) 
Experienced 
Naive 
 
603 (51.0) 
579 (49.0) 
 
8381 (49.5) 
8547 (50.5) 
0.32 
Concomitant ASA, n (%) 556 (47.0) 6597 (39.0) <0.0001 
Statins, n (%) 576 (48.7) 7481 (44.2) 0.0024 
H2 Blockers, n (%) 65 (5.5) 693 (4.1) 0.0196 
ACEi/ARB, n (%) 805 (68.1) 11178 (66.0) 0.14 
Amiodarone, n (%) 113 (9.6) 1863 (11.0) 0.12 
PPI, n (%) 225 (19.0) 2342 (13.8) <0.0001 
CHADS2, median [IQR] 2 [2-3] 2 [1-3] <0.0001 
Legend: *total number of patients with available data about the covariate; ACEi= 
angiotensin converting enzyme inhibitor; ARBs= angiotensin receptor blocker; ASA= 
acetylsalicylic acid; CAD= coronary artery disease; CrCl= creatinine clearance; HF= heart 
failure; IQR= interquartile range; PPI= proton pump inhibitor; SBP= systolic blood pressure; 
SEE= systemic embolic event; TIA= transient ischemic attack; VKA= vitamin K antagonist. 
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Table 2: Bleeding Risk Score Categories According to Major Bleeding Occurrence 
 Overall 
N=18113 
Major bleeding p-value 
No 
N=16931 
Yes 
N=1182 
HAS-BLED, median [IQR] 2 [1-2] 2 [1-2] 2 [1-3] <0.0001 
HAS-BLED Categories, n (%) 
Low (0-2) 
High (>2) 
 
14684 (81.1) 
3429 (18.9) 
 
13874 (81.8) 
3077 (18.2) 
 
810 (69.7) 
352 (30.3) 
<0.0001 
ORBIT, median [IQR] 1 [1-2] 1 [1-2] 2 [1-3] <0.0001 
ORBIT Categories, n (%) 
Low (0-2) 
Intermediate (3) 
High (>3) 
 
14203 (78.4) 
2371 (13.1) 
1539 (8.5) 
 
13517 (79.7) 
2144 (12.6) 
1290 (7.6) 
 
686 (59.0) 
227 (19.5) 
249 (21.4) 
<0.0001 
ATRIA, median [IQR] 0 [0-2] 0 [0-2] 2 [0-3] <0.0001 
ATRIA Categories, n (%) 
Low (0-4) 
Intermediate/High (≥4) 
 
16746 (92.5) 
1367 (7.5) 
 
15787 (93.1) 
1164 (6.9) 
 
959 (82.5) 
203 (17.5) 
<0.0001 
HEMORR2HAGES, median [IQR] 1 [0-2] 1 [0-2] 1 [1-2] <0.0001 
HEMORR2HAGES Categories, n (%) 
Low (0-1) 
Intermediate (2-3) 
High (>3) 
 
12874 (71.1) 
4932 (27.2) 
307 (1.7) 
 
12239 (72.2) 
4449 (26.2) 
263 (1.6) 
 
635 (54.6) 
483 (41.6) 
44 (3.8) 
<0.0001 
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Legend: ATRIA= Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED= 
Hypertension, Abnormal liver/renal function, Stroke, Bleeding, Labile International 
Normalized Ratio, Elderly, Drugs or alcohol; HEMORR2HAGES= Hepatic or renal disease, 
Ethanol abuse, Malignancy history, Older (age >75), Reduced platelet count or function, 
Rebleeding risk, Hypertension, Anaemia, Genetic factors, Excessive fall risk, Stroke history; 
IQR= interquartile range; ORBIT= Older age, Reduced haemoglobin/haematocrit/anaemia, 
Bleeding history, Insufficient kidney function, Treatment with platelets. 
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Table 3: Discriminative Abilities for the Bleeding Risk Scores According to Randomized Treatment and Outcomes Occurrences 
 C-index (95% CI) 
Outcome Risk Score* Overall Dabigatran 110 Dabigatran 150 Warfarin 
Major Bleeding HAS-BLED 0.62  
(0.60-0.63) 
0.61  
(0.58-0.64) 
0.64  
(0.62-0.67) 
0.59  
(0.57-0.62) 
ORBIT 0.66  
(0.65-0.68) 
0.68  
(0.65-0.71) 
0.70  
(0.68-0.73) 
0.62  
(0.59-0.64) 
ATRIA 0.64  
(0.62-0.65) 
0.64  
(0.61-0.67) 
0.67  
(0.65-0.70) 
0.59  
(0.57-0.62) 
HEMORR2HAGES 0.62  
(0.61-0.64) 
0.61  
(0.58-0.64) 
0.66  
(0.64-0.69) 
0.59  
(0.56-0.62) 
Life-Threatening Bleeding HAS-BLED 0.61  
(0.59-0.64) 
0.60  
(0.56-0.64) 
0.65  
(0.61-0.69) 
0.59  
(0.55-0.63) 
ORBIT 0.66  
(0.64-0.68) 
0.67  
(0.63-0.71) 
0.71  
(0.68-0.75) 
0.62  
(0.58-0.65) 
ATRIA 0.63  
(0.61-0.66) 
0.63  
(0.58-0.67) 
0.68  
(0.64-0.72) 
0.59  
(0.56-0.63) 
HEMORR2HAGES 0.62  
(0.60-0.64) 
0.61  
(0.57-0.66) 
0.66  
(0.63-0.70) 
0.59  
(0.56-0.62) 
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Intracranial Bleeding HAS-BLED 0.56  
(0.52-0.61) 
0.52  
(0.42-0.63) 
0.56  
(0.48-0.64) 
0.57  
(0.52-0.63) 
ORBIT 0.62  
(0.57-0.66) 
0.63  
(0.55-0.72) 
0.60  
(0.50-0.69) 
0.62  
(0.57-0.67) 
ATRIA 0.58  
(0.54-0.63) 
0.59  
(0.50-0.69) 
0.59  
(0.50-0.68) 
0.58  
(0.52-0.63) 
HEMORR2HAGES 0.59  
(0.55-0.64) 
0.54  
(0.44-0.65) 
0.61  
(0.52-0.70) 
0.60  
(0.55-0.66) 
Legend: *See Table 2 for risk scores acronyms; CI= confidence interval.  
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Table 4: Discriminative Difference Compared to HAS-BLED According Outcomes* 
 Difference in C-index (95% CI) vs. HAS-BLED 
 Major Bleeding Life-Threatening 
Bleeding 
Intracranial 
Bleeding 
ORBIT 0.050 
(0.036, 0.063) 
0.053 
(0.009, 0.092) 
0.048  
(0.026, 0.067) 
ATRIA 0.021  
(0.005, 0.036) 
0.020  
(-0.032, 0.072) 
0.018  
(-0.008,0.042) 
HEMORR2HAGES 0.006  
(-0.010, 0.020) 
0.030  
(-0.012, 0.076) 
0.007  
(-0.015, 0.029) 
Legend: *See Table 2 for risk scores acronyms; †Bold indicates statistically significant 
results. CI= confidence interval. 
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Supplementary Methods 
 
Definition and Categorization of the Bleeding Risk Scores  
The HAS-BLED score was developed in 2010(1), from data originating from the Euro Heart Survey 
on atrial fibrillation (AF), an observational study by the European Society of Cardiology(2). One 
point each was allocated for the presence of uncontrolled hypertension (systolic blood pressure [BP] 
>160 mmHg), impaired renal or liver function, history of stroke, history of bleeding (or condition 
predisposing to bleeding), labile international normalized ration (INR), elderly (age>65 years), 
concomitant use of aspirin or non-steroidal anti-inflammatory drugs and alcohol consumption (more 
than 20 units a week). The “impaired renal function” variable was considered for a creatinine 
clearance <60 ml/min according the Cockroft-Gault formula. The “impaired liver function” was 
defined as chronic hepatic disease (e.g., cirrhosis) or biochemical evidence of significant hepatic 
derangement (e.g., bilirubin > 2 × upper limit of normal, in association with aspartate 
aminotransferase/alanine aminotransferase/alkaline phosphatase > 3 × upper limit normal). A 
condition predisposing to bleeding was considered for a haemoglobin level <13 g/dL in males or <12 
g/dL in females. Labile INR was defined according the baseline question as part of original study case 
report form (CRF) “Has patient had difficulty with INR control?”. A sensitivity analysis was also 
performed using an alternative definition for labile INR, according INR value at randomization. For 
the sensitivity analysis one point was assigned as an INR value above 3 or an INR value below 2, in 
relation to the vitamin K antagonist discontinuation timing. An HAS-BLED score ≤2 was categorized 
as “low risk”, while HAS-BLED score ≥3 was categorised as “high risk”(3). 
 
The ORBIT score was developed from the “Outcomes registry for better informed treatment of atrial 
fibrillation” study cohort(4, 5), and  calculated as follows: 1 point each for age older than 74, 
insufficient kidney function (defined as a creatinine clearance <60 ml/min according Cockcroft-Gault) 
and treatment with any antiplatelet drug, while 2 points were assigned for a clinical history of 
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bleeding and the presence of anaemia or abnormal haemoglobin (<13 mg/dL for males and <12 
mg/dL for females) or reduced haematocrit (<40% for males and <36% for females). An ORBIT 
score ≤2 was categorised as “low risk”, an ORBIT score equal to 3 as “intermediate risk”, while a 
total score of 4 or higher as “high risk”. 
 
The ATRIA score was developed in 2011 from a derivation cohort of the “Anticoagulation and Risk 
Factors in Atrial Fibrillation” study, a large nationwide observational cohort on AF patients among 
the general population(6). According the original design, three points were assigned for the presence 
of anaemia or concomitant diagnosis of a severe renal disease (creatinine clearance <30 ml/min), 2 
points for age ≥75 years and one point for a positive clinical history of bleeding or diagnosis of 
hypertension. Anemia was considered for haemoglobin level <13 g/dL in males or <12 g/dL in 
females. A total score <4 points was categorized as “low risk”, a score of 4 “intermediate risk”, while 
a score >4 was defined as “high risk”. 
 
The HEMORR2HAGES score was developed in 2006 and derived from the “National Registry of 
Atrial Fibrillation”, comprised of AF patients within a Medicare program(7). The original model 
allocated one point for the following: hepatic or renal disease, ethanol abuse, malignancy, older age 
(≥75 years), reduced platelet count or function, uncontrolled hypertension, anaemia, genetic factors, 
excessive fall risk, history of stroke. Two points were assigned for a positive bleeding history. We 
considered “alcohol abuse” as the consumption of >20 units of alcohol per week. Hepatic and renal 
disease, uncontrolled hypertension and anemia were defined as detailed above. Excessive fall risk was 
considered according the baseline question in CRF “Has the patient had a fall within the last year?”. 
Furthermore, due to the absence of data about genetic factors, this item was not considered for the 
score calculation. Patients were categorized as “low risk” for score of 0-1, “intermediate risk” was 
defined for a score of 2-3, while a score ≥4 was defined as “high risk”.  
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Table S1: Baseline Characteristics According to Randomized Treatment and Major Bleeding Occurrence 
 Dabigatran 110 Dabigatran 150 Warfarin 
Major Bleeding Major Bleeding Major Bleeding 
No 
N=5668 
Yes 
N=347 
No 
N=5667 
Yes 
N=409 
No 
N=5596 
Yes 
N=426 
Age, (years) median [IQR] 72 [66-77] 76 [71-80] 72 [66.0-77.0] 77 [71-81] 72 [67-77] 74 [69-79] 
Age≥75 years, n (%) 2141 (37.8) 208 (59.9) 2214 (39.1) 252 (61.6) 2213 (39.5) 210 (49.3) 
Female, n (%) 2031 (35.8) 118 (34.0) 2090 (36.4) 146 (35.7) 2064 (36.9) 149 (35.0) 
Sitting SBP, (mmHg) median [IQR] (18086)* 130 [120-140] 130 [118-140] 130 [120-140] 130 [119-140] 130 [120-140] 130 [120-140] 
CrCL, (mL/min), median [IQR] (17375)* 69.5 [53.8-88.1] 56.4 [44.4-72.8] 68.5 [53.5-87.2] 58.9 [45.5-76.5] 69.2 [54.3-87.2] 62.0 [49.0-77.0] 
Hypertension, n (%) 4463 (78.8) 275 (79.3) 4449 (78.5) 346 (84.6) 4401 (78.6) 349 (81.9) 
Diabetes Mellitus, n (%) 1302 (23.0) 107 (30.8) 1271 (22.4) 131 (32.0) 1294 (23.1) 116 (27.2) 
Coronary Artery Disease n (%) 1523 (26.9) 138 (39.8) 1555 (27.4) 155 (28.1) 1507 (26.9) 156 (36.6) 
Previous Stroke/SEE/TIA, n (%) 1236 (21.8) 72 (20.7) 1243 (21.9) 115 (28.1) 1185 (21.2) 102 (23.9) 
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Heart Failure, n (%) 1537 (27.1) 104 (30.0) 1542 (27.2) 98 (24.0) 1500 (26.8) 123 (28.9) 
Previous VKA Use, n (%) 
Experienced 
Naive 
 
2840 (50.1) 
2826 (49.9) 
 
168 (48.4) 
179 (51.6) 
 
2831 (50.0) 
2835 (50.0) 
 
216 (52.8) 
193 (47.2) 
 
2710 (48.4) 
2886 (51.6) 
 
219 (51.4) 
207 (48.6) 
CrCL Category, n (%) (17375)* 
<50 mL/min 
50-79 mL/min 
≥80 mL/min 
 
1028 (18.9) 
2558 (47.1) 
1842 (33.9) 
 
123 (36.6) 
156 (46.4) 
57 (17.0) 
 
1064 (19.5) 
2589 (47.5) 
1799 (33.0) 
 
124 (31.4) 
188 (47.6) 
83 (21.0) 
 
968 (18.1) 
2596 (48.6) 
1783 (33.3) 
 
113 (27.1) 
210 (50.4) 
94 (22.5) 
History of Fall, n (%) 628 (11.1) 58 (16.7) 604 (10.7) 89 (21.8) 610 (10.9) 58 (13.6) 
Anemia, n (%) 729 (12.9) 97 (28.0) 699 (12.3) 133 (32.5) 718 (12.8) 97 (22.8) 
Malignancy, n (%) 565 (10.0) 48 (13.8) 582 (10.3) 69 (16.9) 567 (10.1) 54 (12.7) 
Concomitant ASA, n (%) 2840 (50.1) 168 (48.4) 2150 (37.9) 188 (46.0) 2231 (39.9) 200 (46.9) 
Statins, n (%) 2532 (44.7) 170 (49.0) 2477 (43.7) 205 (50.1) 2472 (44.2) 201 (47.2) 
H2 Blockers, n (%) 221 (3.9) 18 (5.2) 228 (4.0) 29 (7.1) 244 (4.4) 18 (4.2) 
ACEi/ARB, n (%) 3749 (66.1) 238 (68.6) 3778 (66.7) 284 (69.4) 3651 (65.2) 283 (66.4) 
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Amiodarone, n (%) 610 (10.8) 37 (10.8) 632 (11.1) 40 (10.0) 622 (11.1) 35 (8.3) 
PPI, n (%) 786 (13.9) 61 (17.6) 790 (13.9) 88 (21.5) 766 (13.7) 76 (17.8) 
CHADS2, median [IQR] 2 [1-3] 2 [2-3] 2 [1-3] 2 [2-3] 2 [1-3] 2 [2-3] 
Legends: *total number of patients with available data about the covariate; ACEi= angiotensin converting enzyme inhibitor; ARBs= angiotensin receptor 
blocker; ASA= acetylsalicylic acid; CrCl= creatinine clearance; IQR= interquartile range; PPI= proton pump inhibitor; SBP= systolic blood pressure; SEE= 
systemic embolic event; TIA= transient ischemic attack; VKA= vitamin K antagonist.  
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Table S2: Bleeding Risk Prediction Scores According Randomized Treatment and Major Bleeding Occurrence 
 Dabigatran 110 Dabigatran 150 W Pint 
Major Bleeding Major Bleeding Major Bleeding 
DE110 vs. W DE150 vs. W No 
N=5668 
Yes 
N=347 
No 
N=5667 
Yes 
N=409 
No 
N=5596 
Yes 
N=426 
HAS-BLED, median [IQR] 2 [1-2] 2 [1-3] 2 [1-2] 2 [2-3] 2 [1-2] 2 [1-3]   
HAS-BLED Categories, n (%) 
Low (0-2) 
High (>2) 
 
4652 (82.1) 
1016 (17.9) 
 
244 (70.3) 
103 (29.7) 
 
4657 (82.2) 
1010 (17.8) 
 
272 (66.5) 
137 (33.5) 
 
4552 (81.3) 
1044 (18.7) 
 
307 (72.1) 
119 (27.9) 
0.5085 0.0607 
ORBIT, median [IQR] 1 [1-2] 2 [1-3] 1 [1-2] 2 [1-3] 1 [1-2] 2 [1-3]   
ORBIT Categories, n (%) 
Low (0-2) 
Intermediate (3) 
High (>3) 
 
4524 (79.8) 
709 (12.5) 
435 (7.7) 
 
203 (58.5) 
71 (20.5) 
73 (21.0) 
 
4519 (79.7) 
745 (13.1) 
403 (7.1) 
 
219 (53.5) 
90 (22.0) 
100 (24.4) 
 
4460 (79.7) 
688 (12.3) 
448 (8.0) 
 
278 (65.3) 
68 (16.0) 
80 (18.8) 
0.1652 0.0019 
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ATRIA, median [IQR] 0 [0-2] 2 [0-3] 0 [0-2] 2 [0-3] 0 [0-2] 2 [0-3]   
ATRIA Categories, n (%) 
Low (0-3) 
Intermediate/High (≥4) 
 
5297 (93.5) 
371 (6.5) 
 
284 (81.8) 
63 (18.2) 
 
5287 (93.3) 
380 (6.7) 
 
318 (77.8) 
91 (22.2) 
 
5187 (92.7) 
409 (7.3) 
 
374 (87.8) 
52 (12.2) 
0.0097 <.0001 
HEMORR2HAGES, median [IQR] 1 [0-2] 1 [1-2] 1 [0-2] 2 [1-2] 1 [0-2] 1 [1-2]   
HEMORR2HAGES Categories, n (%) 
Low (0-1) 
Intermediate (2-3) 
High (>3) 
 
4111 (72.5) 
1475 (26.0) 
82 (1.4) 
 
193 (55.6) 
146 (42.1) 
8 (2.3) 
 
4096 (72.3) 
1485 (26.2) 
86 (1.5) 
 
195 (47.7) 
185 (45.2) 
29 (7.1) 
 
4023 (71.9) 
1479 (26.4) 
94 (1.7) 
 
256 (60.1) 
162 (38.0) 
8 (1.9) 
0.3408 <.0001 
Legend: ATRIA= Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED= Hypertension, Abnormal liver/renal function, Stroke, Bleeding, 
Labile International Normalized Ratio, Elderly, Drugs or alcohol; HEMORR2HAGES= Hepatic or renal disease, Ethanol abuse, Malignancy history, Older 
(age >75), Reduced platelet count or function, Rebleeding risk, Hypertension, Anaemia, Genetic factors, Excessive fall risk, Stroke history; IQR= 
interquartile range; ORBIT= Older age, Reduced haemoglobin/haematocrit/anaemia, Bleeding history, Insufficient kidney function, Treatment with platelets; 
pint= p value for interaction. 
  
	 38 
Table S3: Treatment Interactions for Bleeding Risk Prediction Scores Categories for Secondary Outcomes* 
 Life-Threatening Bleeding Intracranial Bleeding 
D110 vs. W pint D150 vs. W pint D110 vs. W pint D150 vs. W pint 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
HAS-BLED Categories 
Low (0-2) 
High (>2) 
 
0.68 (0.53-0.87) 
0.66 (0.45-0.98) 
0.9118  
0.71 (0.56-0.90) 
1.07 (0.76-1.50) 
0.0574  
0.32 (0.20-0.52) 
0.21 (0.08-0.54) 
0.3977  
0.44 (0.28-0.67) 
0.37 (0.17-0.79) 
0.6925 
ORBIT Categories 
Low (0-2) 
Intermediate (3) 
High (>3) 
 
0.66 (0.51-0.86) 
0.68 (0.42-1.10) 
0.70 (0.43-1.16) 
0.9763  
0.66 (0.51-0.86) 
0.88 (0.57-1.37) 
1.31 (0.85-2.02) 
0.0266  
0.33 (0.20-0.54) 
0.38 (0.15-0.97) 
0.07 (0.01-0.50) 
0.1592  
0.40 (0.25-0.64) 
0.35 (0.14-0.91) 
0.55 (0.23-1.30) 
0.7667 
ATRIA Categories 
Low (0-3) 
Intermediate/High (≥4) 
 
0.63 (0.50-0.78) 
1.12 (0.63-2.00) 
0.0662  
0.71 (0.58-0.88) 
1.70 (1.01-2.88) 
0.0021  
0.30 (0.19-0.46) 
0.25 (0.05-1.20) 
0.8510  
0.39 (0.26-0.58) 
0.72 (0.25-2.09) 
0.2888 
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 Life-Threatening Bleeding Intracranial Bleeding 
D110 vs. W pint D150 vs. W pint D110 vs. W pint D150 vs. W pint 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
HEMORR2HAGES Categories 
Low (0-1) 
Intermediate (2-3) 
High (>3) 
 
0.58 (0.44-0.76) 
0.87 (0.63-1.21) 
0.44 (0.09-2.28) 
0.1523  
0.63 (0.49-0.82) 
1.03 (0.76-1.41) 
2.25 (0.79-6.39) 
0.0073  
0.34 (0.20-0.57) 
0.24 (0.11-0.52) 
0.00 (0.00-.) 
0.3769  
0.39 (0.24-0.65) 
0.41 (0.22-0.76) 
0.92 (0.19-4.54) 
0.6169 
Legend: *See Table S2 for risk scores acronyms; CI= confidence interval; D110= dabigatran 110 mg; D150= dabigatran 150 mg; HR= hazard ratio; pint= p 
value for interaction; W= warfarin. 
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Table S4: Sensitivity Analysis for HAS-BLED According Alternative Definition of “Labile INR” 
 
Major Bleeding 
Annualized Event Rates Treatment Interactions 
HAS-BLED* 
 
Low (0-2) 
High (>2) 
N (%/year) D110 vs. W D150 vs. W 
D110 D150 W HR (95% CI) pint HR (95% CI) pint 
235 (2.45) 258 (2.68) 306 (3.24) 0.75 (0.63-0.89) 0.1340 0.83 (0.70-0.98) 0.0050 
112 (4.83) 151 (6.28) 120 (5.12) 0.95 (0.74-1.23) 1.25 (0.99-1.59) 
Legend: *See Table 2 for risk score acronym; CI= confidence interval; D110= dabigatran etexilate 110 mg; D150= dabigatran etexilate 150 mg; HR= hazard 
ratio; pint= p value for interaction; W= warfarin. 
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Table S5: Sensitivity Analysis of Discriminative Ability for HAS-BLED According Alternative Definition of “Labile INR” 
 Major Bleeding 
C-index (95% CI) 
HAS-BLED* 
Overall Dabigatran 110 Dabigatran 150 Warfarin 
0.60 (0.59-0.62) 0.60 (0.58-0.63) 0.62 (0.60-0.65) 0.59 (0.56-0.61) 
Legend: *See Table 2 for risk score acronym; CI= confidence interval. 
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